Literature DB >> 3348944

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

R J Osborne1, S T Malik, M L Slevin, V J Harvey, J Spona, H Salzer, C J Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3348944      PMCID： PMC2246673          DOI： 10.1038/bjc.1988.22

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  Androgen and oestrogen binding in cytosols of human ovarian tumours.

Authors:  T C Hamilton; P Davies; K Griffiths
Journal:  J Endocrinol       Date:  1981-09       Impact factor: 4.286

2.  Tamoxifen therapy of epithelial ovarian cancer.

Authors:  D R Shirey; J J Kavanagh; D M Gershenson; R S Freedman; L J Copeland; L A Jones
Journal:  Obstet Gynecol       Date:  1985-10       Impact factor: 7.661

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.

Authors:  P M Wilkinson; G G Ribiero; H K Adam; J V Kemp; J S Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

5.  Estrogen and progestin binding in cytosols of ovarian adenocarcinomas.

Authors:  J A Holt; T A Caputo; K M Kelly; P Greenwald; S Chorost
Journal:  Obstet Gynecol       Date:  1979-01       Impact factor: 7.661

6.  Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors.

Authors:  T Bäckström; C G Mählck; O Kjellgren
Journal:  Gynecol Oncol       Date:  1983-08       Impact factor: 5.482

7.  Advanced ovarian carcinoma: response to antiestrogen therapy.

Authors:  A M Myers; G E Moore; F J Major
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

8.  In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy.

Authors:  H M Runge; G Teufel; J Neulen; H Geyer; A Pfleiderer
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Peripheral venous concentrations of oestrogens in postmenopausal women with ovarian cancer.

Authors:  P K Heinonen; R Tuimala; K Pyykkö; P Pystynen
Journal:  Br J Obstet Gynaecol       Date:  1982-01

10.  A phase II study of tamoxifen in ovarian cancer.

Authors:  M L Slevin; V J Harvey; R J Osborne; J H Shepherd; C J Williams; G M Mead
Journal:  Eur J Cancer Clin Oncol       Date:  1986-03
View more
  7 in total

1.  Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.

Authors:  Rajul Kothari; Peter Argenta; Jeffrey Fowler; Jori Carter; William Shimp
Journal:  Arch Oncol       Date:  2010

Review 2.  Tamoxifen for relapse of ovarian cancer.

Authors:  Chris Williams; Iveta Simera; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 3.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

Review 4.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

5.  Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.

Authors:  S P Langdon; M M Hawkes; S S Lawrie; R A Hawkins; A L Tesdale; A J Crew; W R Miller; J F Smyth
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

6.  The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.

Authors:  P Thompson; P Wilson; R Osborne; M Slevin; F Wiltshaw; P Blake; P Harper; R Coleman; C Williams; J Sweetenham
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

Review 7.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.